Renaissance Capital logo

Calithera Biosciences Priced, Nasdaq: CALA

Early-stage biotech developing a drug platform that inhibits tumor metabolism.

Industry: Health Care

First Day Return: -5.9%

Industry: Health Care

Early-stage biotech developing a drug platform that inhibits tumor metabolism.
more less

Calithera Biosciences (CALA) Performance